We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
-$194M
Cap. Flow %
-10.24%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Miscellaneous 20.04%
3 Real Estate 5.59%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QGEN icon
26
CALL
Qiagen
QGEN
$8.9B
$19.1M 1.01%
+476,300
New +$22.5M
EHC icon
27
Encompass Health
EHC
$11.9B
$18.8M 0.99%
194,104
+87,178
+82% +$8.94M
LLY icon
28
Eli Lilly
LLY
$1.05T
$17.5M 0.92%
19,000
+8,377
+79% +$8.49M
TVTX icon
29
Travere Therapeutics
TVTX
$6.19B
$16.1M 0.85%
542,610
-632,358
-54% -$18.9M
INSM icon
30
CALL
Insmed
INSM
$25.9B
$15.4M 0.81%
+94,000
New +$14.5M
CTMX icon
31
CytomX Therapeutics
CTMX
$699M
$15M 0.79%
3,188,514
+681,424
+27% +$3.46M
HYG icon
32
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.6B
$14.3M 0.76%
+180,000
New +$14.5M
RGEN icon
33
Repligen
RGEN
$9.95B
$14.2M 0.75%
+120,785
New +$16.9M
BBNX
34
Beta Bionics
BBNX
$887M
$14.2M 0.75%
1,414,838
+736,576
+109% +$10.9M
VRDN icon
35
Viridian Therapeutics
VRDN
$2.61B
$14M 0.74%
713,269
-1,068,966
-60% -$31.7M
ARQT icon
36
Arcutis Biotherapeutics
ARQT
$2.99B
$13.6M 0.72%
576,580
+141,946
+33% +$3.62M
ARDX icon
37
Ardelyx
ARDX
$984M
$13.4M 0.7%
2,229,446
+514,317
+30% +$3.4M
LTC
38
LTC Properties
LTC
$2.19B
$11.9M 0.63%
+321,046
New +$12.1M
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$12.5B
$11.7M 0.62%
207,768
+114,020
+122% +$6.65M
CHE icon
40
Chemed
CHE
$6.84B
$11.7M 0.62%
+31,057
New +$13.3M
PHVS icon
41
Pharvaris
PHVS
$2.48B
$11.5M 0.61%
406,960
-32,217
-7% -$860K
UNH icon
42
CALL
UnitedHealth
UNH
$353B
$10.8M 0.57%
+40,000
New +$11.9M
IWM icon
43
PUT
iShares Russell 2000 ETF
IWM
$80.8B
$9.92M 0.52%
+40,000
New +$10.3M
PNTG icon
44
Pennant Group
PNTG
$1.3B
$9.52M 0.5%
312,178
+18,218
+6% +$563K
XLK icon
45
PUT
State Street Technology Select Sector SPDR ETF
XLK
$121B
$9.3M 0.49%
+70,000
New +$9.86M
NAMS icon
46
NewAmsterdam Pharma
NAMS
$3.1B
$9.15M 0.48%
285,764
-135,063
-32% -$4.4M
PALI icon
47
Palisade Bio
PALI
$349M
$8.73M 0.46%
4,987,499
-404,049
-7% -$735K
MRNA icon
48
Moderna
MRNA
$55.1B
$8.11M 0.43%
159,708
-108,115
-40% -$5.04M
VKTX icon
49
Viking Therapeutics
VKTX
$3.75B
$7.78M 0.41%
+239,110
New +$7.69M
ICLR icon
50
Icon
ICLR
$13.1B
$7.6M 0.4%
68,688
-27,144
-28% -$3.71M

Similar funds

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners withdrew a net $194M in Q1 2026, closing 31 positions and reducing 36 holdings. Its most notable exit was Danaher, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Eversept Partners opened a new position in Welltower worth $35.8M.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.